Vevoctadekin is under clinical development by Simcha Therapeutics and currently in Phase I for Myelodysplastic Syndrome. According to GlobalData, Phase I drugs for Myelodysplastic Syndrome have a 76% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Vevoctadekin’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Vevoctadekin overview
Vevoctadekin (ST-067) is under development for the treatment of solid tumors including melanoma, renal cell carcinoma, triple-negative breast cancer, non-small cell lung cancer, merkel cell carcinoma, urothelial cancer, gastric cancer, cervical cancer, small-cell lung cancer, cutaneous squamous cell carcinoma, platinum resistant ovarian cancer, endometrial cancer, esophageal cancer, relapsed/refractory acute myeloid leukemia, myelodysplastic syndrome, hepatocellular carcinoma and head and neck squamous cell carcinoma and unspecified indication, relapsed or refractory multiple myeloma. The drug candidates is engineered interleukin-18. It is administered through subcutaneous route.
Simcha Therapeutics overview
Simcha Therapeutics, is a biotechnology company that engaged in developing biologic drugs. The company is headquartered in United States.
For a complete picture of Vevoctadekin’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
